Company Overview
Snapshot
Founded in January 2011 by Orgad Laub, Sealantium Medical operates with 1–10 employees. The company has raised $11.57 million across two funding rounds, with Biotech Alliances International participating. In June 2023, Sealantium Medical announced the completion of its Phase I/II clinical study.
Business overview
Sealantium Medical is a biosurgery company specializing in the development of advanced tissue sealants and hemostatic agents for surgical applications. Its core product, sFilm-FS™, is a biodegradable and biocompatible polymeric film containing Fibrin Sealant, designed to accelerate fluid coagulation and site adhesion. This technology aims to improve surgical performance by reducing the amount of Fibrin Sealant needed and speeding up sealing times. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering, serving the global healthcare market.
Strategic signal
In June 2023, Sealantium Medical announced the completion of its Phase I/II clinical study. This milestone is significant as it indicates the company's progress in clinical development, moving its sFilm-FS product closer to market. Successful completion of early-phase clinical trials provides crucial validation of the product's safety and initial efficacy, signaling to investors and the industry the potential for a novel solution in biosurgery.
Log in to access full profile ›Company Intelligence Q&A
- What is Sealantium Medical's flagship product?
- Sealantium Medical's flagship product is sFilm-FS™, a proprietary biodegradable and biocompatible polymeric film containing Fibrin Sealant designed for tissue sealing and hemostasis during surgery.
- When was Sealantium Medical founded and by whom?
- Sealantium Medical was founded in January 2011 by Orgad Laub.
- What was a key development for Sealantium Medical in June 2023?
- In June 2023, Sealantium Medical announced the completion of its Phase I/II clinical study for sFilm-FS™, which demonstrated promising early clinical results for safety and faster performance in controlling liver bleeding.
- Which firm was retained to lead a Series B capital raise?
- In November 2017, Sealantium Medical retained.
- What is the total capital raised by Sealantium Medical?
- Sealantium Medical has raised a total of $11.57 million across two funding rounds.